Chemicals · Founded 1989 · www.laxmi.com · BSE 543277 · NSE LXCHEM · ISIN INE576O01020
No Notes Added Yet
Business
Laxmi Organic Industries Ltd. is a leading manufacturer of specialty chemicals and intermediates. The company primarily operates in two key business segments: Acetyl Intermediates and Specialty Intermediates. It manufactures a diversified product portfolio used in various industries such as pharmaceuticals, agrochemicals, dyes & pigments, inks & coatings, printing & packaging, and other industrial applications. The company makes money by producing and selling these chemical products, catering to both domestic and international customers.
Revenue Mix
The company's operations are divided into two main segments:
Acetyl Intermediates: This segment includes products like Ethyl Acetate, Acetic Anhydride, and Diketene derivatives. Laxmi Organic is one of the largest manufacturers of Ethyl Acetate in India.
Specialty Intermediates: This segment focuses on more complex, higher-value-added chemicals tailored for specific applications, primarily serving the pharmaceutical, agrochemical, and pigment industries. These products typically offer better margins.
(Specific revenue contribution percentages are not provided here as they fluctuate and are best sourced from recent financial reports).
Industry
Laxmi Organic operates in the diverse Indian chemical industry, which benefits from strong domestic demand and increasing global outsourcing trends ("China Plus One"). The Acetyl Intermediates market is relatively commoditized but benefits from scale, where Laxmi Organic holds a leading position for products like Ethyl Acetate. The Specialty Intermediates market is more fragmented, characterized by high intellectual capital, R&D intensity, and tailored solutions. Laxmi Organic is strategically positioned to capitalize on both segments, leveraging its scale in bulk chemicals and its technical capabilities and customer relationships in niche specialty chemicals.
MOAT
Scale & Cost Leadership: For its Acetyl Intermediates segment (e.g., Ethyl Acetate), the company possesses significant production capacities, leading to economies of scale and cost efficiencies.
Vertical Integration: Backward integration into key raw materials like ethanol and acetic acid (for derivatives like diketene) enhances supply security and cost control, reducing dependence on external volatile inputs.
Product Diversification & Niche Specialization: A broad product portfolio across two distinct segments, with a growing focus on higher-margin Specialty Intermediates, provides resilience and caters to diverse customer needs.
R&D Capabilities: A focus on R&D allows the company to develop new products, improve existing processes, and offer customized solutions, particularly in the Specialty Intermediates segment.
Customer Relationships: Long-standing relationships with a diversified customer base across various industries.
Growth Drivers
Increasing Demand from End-User Industries: Growing pharmaceutical, agrochemical, dyes, inks, and coatings sectors in India and globally will drive demand for its products.
"China Plus One" Strategy: Global manufacturers diversifying their supply chains away from China can lead to increased export opportunities for Indian chemical companies like Laxmi Organic.
Capacity Expansion: Ongoing and planned capital expenditures for expanding existing capacities and setting up new manufacturing lines will support higher sales volumes.
New Product Development: Introduction of new value-added products, especially in the Specialty Intermediates segment, can enhance margins and market share.
Backward Integration: Further investments in backward integration projects can improve cost structures and reduce supply chain risks.
Risks
Raw Material Price Volatility: Fluctuations in the prices of key raw materials such as ethanol, acetic acid, and crude oil derivatives can significantly impact profit margins.
Environmental Regulations: Stringent environmental norms and compliance costs could increase operational expenses or necessitate significant capital expenditure.
Currency Fluctuations: As a company involved in both exports and imports, adverse movements in foreign exchange rates can impact profitability.
Competition: Intense competition from both domestic and international players can lead to pricing pressures and margin erosion.
Global Economic Slowdown: A slowdown in the global economy could reduce demand from end-user industries, affecting sales volumes and pricing.
Project Execution Risk: Delays or cost overruns in capacity expansion projects could impact projected returns and growth timelines.
Management & Ownership
Laxmi Organic Industries Ltd. is promoted by the Goenka family, with Mr. Ravi Goenka serving as the Chairman and Managing Director. The management team has extensive experience in the chemical industry, with a focus on operational efficiency, R&D, and strategic expansion. The company is promoter-led, with a significant stake held by the founding family, alongside institutional investors and public shareholders.
Outlook
Laxmi Organic is well-positioned to benefit from the secular growth trends in the Indian chemical industry, driven by increasing domestic consumption and the global "China Plus One" diversification strategy. Its integrated business model, leading position in Acetyl Intermediates, and growing focus on higher-margin Specialty Intermediates provide a degree of resilience and growth potential. However, the company remains susceptible to volatility in raw material prices, intense competition, and potential disruptions from global economic shifts and regulatory changes. Its ability to successfully execute expansion plans and continue developing new products in the specialty chemicals domain will be key to its sustained long-term growth.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 792 | 718 | 771 | 786 | 710 | 693 | 700 | 719 | 735 | 968 |
| Other Income | 8 | 12 | 7 | 6 | 1 | 6 | 4 | 3 | 3 | 3 |
| Total Income | 800 | 730 | 778 | 792 | 711 | 698 | 704 | 722 | 738 | 972 |
| Total Expenditure | 702 | 647 | 697 | 712 | 651 | 662 | 663 | 669 | 682 | 854 |
| Operating Profit | 98 | 83 | 81 | 80 | 60 | 36 | 41 | 53 | 56 | 118 |
| Interest | -1 | 3 | 8 | 2 | 7 | 5 | 6 | 7 | 5 | 4 |
| Depreciation | 31 | 26 | 27 | 31 | 40 | 17 | 20 | 20 | 19 | 22 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 68 | 54 | 46 | 47 | 13 | 14 | 15 | 26 | 32 | 92 |
| Provision for Tax | 24 | 20 | 18 | 18 | -9 | -7 | 4 | 0 | 11 | 24 |
| Profit After Tax | 44 | 34 | 28 | 29 | 22 | 21 | 11 | 25 | 22 | 68 |
| Adjustments | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 44 | 34 | 28 | 29 | 22 | 21 | 11 | 25 | 22 | 68 |
| Adjusted Earnings Per Share | 1.6 | 1.2 | 1 | 1.1 | 0.8 | 0.8 | 0.4 | 0.9 | 0.8 | 2.4 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 1047 | 1076 | 1376 | 1569 | 1534 | 1768 | 3084 | 2791 | 2865 | 2985 | 2847 | 3122 |
| Other Income | 2 | 2 | 3 | 6 | 4 | 5 | 15 | 18 | 28 | 25 | 15 | 13 |
| Total Income | 1048 | 1078 | 1379 | 1574 | 1539 | 1773 | 3099 | 2809 | 2893 | 3011 | 2862 | 3136 |
| Total Expenditure | 966 | 955 | 1224 | 1413 | 1418 | 1549 | 2713 | 2549 | 2609 | 2706 | 2675 | 2868 |
| Operating Profit | 82 | 123 | 154 | 161 | 121 | 224 | 386 | 260 | 284 | 305 | 187 | 268 |
| Interest | 19 | 14 | 11 | 19 | 17 | 19 | 19 | 15 | 7 | 20 | 22 | 22 |
| Depreciation | 29 | 28 | 29 | 44 | 49 | 47 | 48 | 72 | 107 | 124 | 77 | 81 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 34 | 81 | 114 | 98 | 81 | 158 | 319 | 173 | 171 | 161 | 88 | 165 |
| Provision for Tax | 8 | 10 | 38 | 25 | 11 | 31 | 61 | 48 | 50 | 47 | 9 | 39 |
| Profit After Tax | 27 | 71 | 76 | 72 | 70 | 127 | 257 | 125 | 121 | 114 | 79 | 126 |
| Adjustments | -0 | 0 | 0 | 0 | -0 | -0 | -0 | -0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 27 | 71 | 76 | 72 | 70 | 127 | 257 | 125 | 121 | 114 | 79 | 126 |
| Adjusted Earnings Per Share | 4.2 | 11.3 | 12.2 | 2.9 | 3.1 | 4.8 | 9.8 | 4.7 | 4.4 | 4.1 | 2.9 | 4.5 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | -5% | 1% | 10% | 11% |
| Operating Profit CAGR | -39% | -10% | -4% | 9% |
| PAT CAGR | -31% | -14% | -9% | 11% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -13% | -14% | -20% | NA% |
| ROE Average | 4% | 6% | 10% | 15% |
| ROCE Average | 5% | 8% | 12% | 16% |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 235 | 305 | 380 | 450 | 427 | 1035 | 1290 | 1412 | 1798 | 1907 | 1986 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Borrowings | 75 | 42 | 53 | 75 | 90 | 10 | 2 | 130 | 97 | 43 | 493 |
| Other Non-Current Liabilities | 20 | 11 | 18 | 30 | 23 | 25 | 25 | 39 | 109 | 47 | 42 |
| Total Current Liabilities | 302 | 279 | 427 | 460 | 529 | 768 | 932 | 830 | 1024 | 1275 | 1158 |
| Total Liabilities | 632 | 637 | 878 | 1014 | 1069 | 1838 | 2249 | 2412 | 3028 | 3271 | 3679 |
| Fixed Assets | 215 | 202 | 279 | 346 | 338 | 325 | 379 | 715 | 879 | 1166 | 1481 |
| Other Non-Current Assets | 59 | 76 | 55 | 44 | 93 | 207 | 398 | 481 | 539 | 472 | 706 |
| Total Current Assets | 359 | 358 | 544 | 625 | 639 | 1305 | 1473 | 1217 | 1610 | 1633 | 1493 |
| Total Assets | 632 | 637 | 878 | 1014 | 1069 | 1838 | 2249 | 2412 | 3028 | 3271 | 3679 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 8 | 9 | 12 | 5 | 8 | 24 | 17 | 34 | 81 | 111 | 42 |
| Cash Flow from Operating Activities | 80 | 143 | -32 | 188 | 196 | 106 | 65 | 199 | 561 | 108 | 175 |
| Cash Flow from Investing Activities | -21 | -36 | -85 | -123 | -56 | -641 | 55 | -384 | -490 | -268 | -404 |
| Cash Flow from Financing Activities | -57 | -104 | 110 | -63 | -123 | 527 | -124 | 232 | -42 | 90 | 247 |
| Net Cash Inflow / Outflow | 1 | 3 | -7 | 2 | 16 | -7 | -4 | 47 | 30 | -70 | 19 |
| Closing Cash & Cash Equivalent | 9 | 12 | 5 | 8 | 24 | 17 | 34 | 81 | 111 | 42 | 60 |
| # | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 4.25 | 11.29 | 12.19 | 2.89 | 3.11 | 4.82 | 9.76 | 4.7 | 4.37 | 4.1 | 2.86 |
| CEPS(Rs) | 8.91 | 15.76 | 16.9 | 4.65 | 5.29 | 6.58 | 11.59 | 7.43 | 8.24 | 8.57 | 5.63 |
| DPS(Rs) | 0.16 | 0.19 | 0.24 | 0.07 | 0 | 0.5 | 0.7 | 0.5 | 0.6 | 0.5 | 0.3 |
| Book NAV/Share(Rs) | 37.52 | 48.71 | 60.73 | 17.98 | 18.97 | 39.06 | 47.87 | 52.29 | 64.24 | 68.16 | 70.63 |
| Core EBITDA Margin(%) | 7.23 | 10.55 | 10.86 | 9.9 | 7.6 | 12.4 | 12.04 | 8.69 | 8.88 | 9.37 | 6.02 |
| EBIT Margin(%) | 4.77 | 8.27 | 8.96 | 7.43 | 6.38 | 10.03 | 10.95 | 6.73 | 6.16 | 6.06 | 3.87 |
| Pre Tax Margin(%) | 3.08 | 7.08 | 8.17 | 6.22 | 5.27 | 8.96 | 10.34 | 6.2 | 5.93 | 5.38 | 3.09 |
| PAT Margin (%) | 2.39 | 6.17 | 5.47 | 4.62 | 4.58 | 7.19 | 8.35 | 4.46 | 4.19 | 3.8 | 2.79 |
| Cash Profit Margin (%) | 5.01 | 8.61 | 7.59 | 7.42 | 7.77 | 9.82 | 9.91 | 7.06 | 7.89 | 7.96 | 5.48 |
| ROA(%) | 4.29 | 11.13 | 10.07 | 7.65 | 6.74 | 8.74 | 12.6 | 5.35 | 4.43 | 3.6 | 2.28 |
| ROE(%) | 12.01 | 26.18 | 22.28 | 17.45 | 16.02 | 17.44 | 22.46 | 9.41 | 7.63 | 6.2 | 4.13 |
| ROCE(%) | 11.63 | 21.56 | 24.54 | 19.1 | 16.16 | 20.14 | 26 | 11.62 | 9.48 | 8.84 | 4.7 |
| Receivable days | 62.08 | 67.28 | 72.75 | 75.67 | 81.55 | 81.94 | 65.27 | 80.99 | 73.16 | 68.54 | 68.05 |
| Inventory Days | 33.55 | 31.2 | 28.88 | 36.83 | 38.38 | 36.65 | 34.15 | 43.68 | 36.62 | 40.42 | 47.64 |
| Payable days | 60.97 | 75.22 | 71.13 | 88.23 | 121.68 | 137.79 | 101.88 | 115.88 | 116.48 | 136.74 | 136.38 |
| PER(x) | 0 | 0 | 0 | 0 | 0 | 36.17 | 40.93 | 47.43 | 53.85 | 42.79 | 37.7 |
| Price/Book(x) | 0 | 0 | 0 | 0 | 0 | 4.46 | 8.35 | 4.26 | 3.66 | 2.57 | 1.53 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0.29 | 0.18 | 0.22 | 0.25 | 0.29 | 0.28 |
| EV/Net Sales(x) | 0.21 | 0.1 | 0.16 | 0.11 | 0.11 | 2.37 | 3.4 | 2.21 | 2.2 | 1.67 | 1.22 |
| EV/Core EBITDA(x) | 2.64 | 0.85 | 1.42 | 1.11 | 1.38 | 18.74 | 27.16 | 23.73 | 22.22 | 16.36 | 18.59 |
| Net Sales Growth(%) | -2.54 | 2.8 | 27.85 | 14.03 | -2.19 | 15.27 | 74.41 | -9.5 | 2.65 | 4.2 | -4.65 |
| EBIT Growth(%) | -8.18 | 78.18 | 31.9 | -6.68 | -16.03 | 81.33 | 90.4 | -44.41 | -5.56 | 2.05 | -39.19 |
| PAT Growth(%) | 25.72 | 165.08 | 8.04 | -5.08 | -2.97 | 80.9 | 102.59 | -51.59 | -3.27 | -5.83 | -30.08 |
| EPS Growth(%) | 25.71 | 165.62 | 8.04 | -76.27 | 7.66 | 54.7 | 102.57 | -51.87 | -6.96 | -6.26 | -30.11 |
| Debt/Equity(x) | 0.94 | 0.39 | 0.57 | 0.39 | 0.37 | 0.14 | 0.11 | 0.29 | 0.08 | 0.13 | 0.28 |
| Current Ratio(x) | 1.19 | 1.29 | 1.28 | 1.36 | 1.21 | 1.7 | 1.58 | 1.47 | 1.57 | 1.28 | 1.29 |
| Quick Ratio(x) | 0.79 | 1.02 | 0.93 | 0.99 | 0.92 | 1.44 | 1.18 | 1.11 | 1.3 | 0.98 | 0.97 |
| Interest Cover(x) | 2.83 | 6.92 | 11.28 | 6.15 | 5.74 | 9.34 | 17.83 | 12.63 | 27.08 | 8.85 | 4.98 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0.03 | 0.01 | 0.07 | 0.02 | 0.05 | 0.18 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 69.72 | 69.55 | 69.5 | 69.38 | 69.38 | 69.37 | 69.35 | 69.35 | 69.35 | 69.34 |
| FII | 0.85 | 1.05 | 1.67 | 1.97 | 2.48 | 1.63 | 1.6 | 1.6 | 1.15 | 0.69 |
| DII | 3.44 | 2.15 | 3.21 | 3.47 | 3.38 | 4.05 | 3.2 | 3.39 | 3.82 | 3.83 |
| Public | 26 | 27.25 | 25.62 | 25.18 | 24.76 | 24.94 | 25.85 | 25.66 | 25.68 | 26.15 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 19.23 | 19.23 | 19.22 | 19.22 | 19.22 | 19.22 | 19.22 | 19.22 | 19.22 | 19.22 |
| FII | 0.23 | 0.29 | 0.46 | 0.55 | 0.69 | 0.45 | 0.44 | 0.44 | 0.32 | 0.19 |
| DII | 0.95 | 0.6 | 0.89 | 0.96 | 0.94 | 1.12 | 0.89 | 0.94 | 1.06 | 1.06 |
| Public | 7.17 | 7.53 | 7.09 | 6.97 | 6.86 | 6.91 | 7.16 | 7.11 | 7.12 | 7.25 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 27.58 | 27.65 | 27.66 | 27.7 | 27.7 | 27.71 | 27.71 | 27.71 | 27.71 | 27.72 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | -5% | +1% | +10% | +11% |
| Operating Profit CAGR | -39% | -10% | -4% | +9% |
| PAT CAGR | -31% | -14% | -9% | +11% |
| Share Price CAGR | -13% | -14% | -20% | — |
| ROE Average | +4% | +6% | +10% | +15% |
| ROCE Average | +5% | +8% | +12% | +16% |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 69.72 | 69.55 | 69.5 | 69.38 | 69.38 | 69.37 | 69.35 | 69.35 | 69.35 | 69.34 |
| FII | 0.85 | 1.05 | 1.67 | 1.97 | 2.48 | 1.63 | 1.6 | 1.6 | 1.15 | 0.69 |
| DII | 3.44 | 2.15 | 3.21 | 3.47 | 3.38 | 4.05 | 3.2 | 3.39 | 3.82 | 3.83 |
| Public | 26 | 27.25 | 25.62 | 25.18 | 24.76 | 24.94 | 25.85 | 25.66 | 25.68 | 26.15 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 19.23 | 19.23 | 19.22 | 19.22 | 19.22 | 19.22 | 19.22 | 19.22 | 19.22 | 19.22 |
| FII | 0.23 | 0.29 | 0.46 | 0.55 | 0.69 | 0.45 | 0.44 | 0.44 | 0.32 | 0.19 |
| DII | 0.95 | 0.6 | 0.89 | 0.96 | 0.94 | 1.12 | 0.89 | 0.94 | 1.06 | 1.06 |
| Public | 7.17 | 7.53 | 7.09 | 6.97 | 6.86 | 6.91 | 7.16 | 7.11 | 7.12 | 7.25 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 27.58 | 27.65 | 27.66 | 27.7 | 27.7 | 27.71 | 27.71 | 27.71 | 27.71 | 27.72 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.